首页> 外国专利> PHARMACEUTICAL COMPOSITION INCLUDING MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND SPHEROIDAL PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND METHOD OF PREPARING THE PHARMACEUTICAL COMPOSITION

PHARMACEUTICAL COMPOSITION INCLUDING MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND SPHEROIDAL PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND METHOD OF PREPARING THE PHARMACEUTICAL COMPOSITION

机译:药物组合物及其制备方法,所述药物组合物包括包含艾美拉唑和类脂药物可接受的盐的多单位球形片剂,以及制备药物组合物的方法

摘要

Provided are a pharmaceutical composition including a core in a form of a multi-unit spheroidal tablet (MUST) containing esomeprazole or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is dissolved by 50 percent (%) or more within 15 minutes of an in vitro dissolution test; and a method of preparing the pharmaceutical composition. According to this, in case that the pharmaceutical composition is developed as the multi-unit spheroidal tablet, the dissolution may be accelerated in a condition of a slow stirring rate than that of a conventional pellet formulation or single tablet. Also, proton pump inhibitors (PPI)-based drugs including esomeprazole may be dissociated by gastric acid having a low pH, consequently inducing a decrease in bioavailability of the drug, but the pharmaceutical composition according to this may be minimize this.
机译:提供了一种药物组合物,其包含以埃索美拉唑或其药学上可接受的盐的多单位球状片剂(MUST)形式的核,其中所述药物组合物在≤15分钟内溶解50%(%)或更多。 I>体外溶出试验以及制备药物组合物的方法。据此,在将药物组合物开发为多单位球状片剂的情况下,可以在比常规丸剂或单一片剂慢的搅拌速度的条件下促进溶解。而且,包括埃索美拉唑的基于质子泵抑制剂(PPI)的药物可以通过具有低pH的胃酸解离,因此引起药物的生物利用度降低,但是根据此的药物组合物可以使其最小化。

著录项

  • 公开/公告号WO2019066555A1

    专利类型

  • 公开/公告日2019-04-04

    原文格式PDF

  • 申请/专利权人 HANMI PHARM. CO. LTD.;

    申请/专利号WO2018KR11528

  • 申请日2018-09-28

  • 分类号A61K9/20;A61K9/28;A61K9/48;A61K31/4439;

  • 国家 WO

  • 入库时间 2022-08-21 11:55:24

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号